Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects strong financial performance with $848 million in revenue and growth potential driven by LIBTAYO and EYLEA HD. The Q&A session provides insights into strategic collaborations and product development, with management addressing concerns and emphasizing potential in various therapeutic areas. Despite some uncertainties, the company's robust pipeline and strategic initiatives, including share repurchases, suggest positive market sentiment. The absence of major negative factors and the focus on growth and shareholder returns support a positive stock price movement prediction.
Key Financial Performance
Total Revenues Increased 19% compared to the first quarter of 2025. This growth was attributed to strong commercial execution across key growth products and continued pipeline progress.
Non-GAAP Earnings Per Share Increased 15% year-over-year, reflecting strong operating performance while continuing to invest in science and long-term growth opportunities.
Global Dupixent Net Sales Increased 31% on a constant currency basis to $4.9 billion in the quarter. Growth was driven by strong demand across multiple approved indications and geographies.
EYLEA HD U.S. Net Product Sales Increased 52% year-over-year to $468 million. Growth was attributed to encouraging physician adoption and confidence in its clinical profile and dosing flexibility.
Global Libtayo Net Product Sales Grew 54% to $438 million, driven by uptake in advanced cutaneous squamous cell carcinoma, advanced non-small cell lung cancer, and early contributions from the adjuvant CSCC indication.
Sanofi Collaboration Revenues Increased 42% year-over-year to $1.6 billion, driven by Dupixent sales growth and improving collaboration margins.
EYLEA and EYLEA 8 mg Net Sales Outside the U.S. Totaled $729 million, inclusive of $333 million of EYLEA 8 mg sales. Growth was supported by international demand.
Other Revenue Grew 109% in the first quarter to $171 million, including $101 million related to profits from ARCALYST and royalty income from Alaris.
Free Cash Flow Generated $848 million in the first quarter of 2026, reflecting strong financial performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Dupixent: Global net sales increased 31% to $4.9 billion, driven by strong demand across multiple approved indications and geographies. Expanded eligible patient population to younger age groups and new diseases.
EYLEA HD: U.S. net product sales increased 52% year-over-year to $468 million. Encouraging physician adoption due to clinical profile and dosing flexibility. FDA decision on pre-filled syringe application expected this quarter.
Libtayo: Global net product sales grew 54% to $438 million, driven by uptake in advanced cutaneous squamous cell carcinoma, advanced non-small cell lung cancer, and adjuvant CSCC indication.
Otarmeni: FDA approval for genetic hearing loss. Product offered for free to patients, reflecting commitment to benefit humanity.
Hansoh collaboration: Positive Phase III data in China for olatorepatide, a GLP/GIP receptor agonist for obesity. Full data expected later this year.
Most-Favored-Nation Pricing agreement: Agreement with the U.S. government to lower drug prices while preserving innovation.
Revenue and earnings growth: Total revenues increased 19% and non-GAAP earnings per share increased 15% compared to Q1 2025.
Capital allocation: Board authorized a new $3 billion share repurchase program. Continued investments in internal growth and strategic collaborations.
Rare disease portfolio expansion: FDA approval of Otarmeni and anticipated decision on garetosmab for FOP in August 2026.
Strategic collaborations: Entered into collaborations with Telix and TriNetX to enhance radiopharmaceutical therapies and access to global patient data.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA approval delays: The FDA did not act by the April 2026 PDUFA date for the company's regulatory application for a second contract manufacturer for the EYLEA HD pre-filled syringe. This application remains pending, and the company is working closely with the FDA to resolve outstanding issues.
Manufacturing disruptions: A temporary interruption in bulk manufacturing at the Limerick, Ireland site negatively impacted GAAP gross margins. Although production has resumed, full production is expected by the end of the second quarter.
Competitive pressures: EYLEA faces competitive pressures and patient affordability issues, which have led to a 36% year-over-year decline in U.S. net sales for the original EYLEA product.
Biosimilar competition: The potential launch of additional biosimilars in the second half of the year is expected to negatively impact demand for EYLEA.
Regulatory and payer challenges: The company faces challenges related to drug pricing regulations, payer coverage, and reimbursement, which could impact financial performance.
Economic uncertainties: Patient affordability issues are highlighted as a concern, potentially impacting demand for certain products.
Supply chain and regulatory risks: The company is working with third-party filling manufacturers and the FDA to resolve outstanding issues related to EYLEA HD pre-filled syringe applications, which could delay product availability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EYLEA HD and EYLEA: Sequential unit demand growth for EYLEA HD is expected to be consistent with the 10% sequential demand growth in the first quarter. Conversely, demand for EYLEA is anticipated to decline in the mid- to high teens in the second quarter due to potential launch of additional biosimilars in the second half of the year and other factors.
Dupixent: Dupixent is well positioned for sustained growth with annualized global net sales of nearly $20 billion and significant room for further market penetration across indications.
Libtayo: Continued growth is expected through 2026 as the company gains incremental share in lung cancer and drives uptake in adjuvant CSCC.
Cemdisiran: Regulatory decision for cemdisiran in generalized myasthenia gravis is expected in the fourth quarter of 2026, with significant commercial opportunity in this large and growing market.
Garetosmab: FDA decision on garetosmab for fibrodysplasia ossificans progressiva is anticipated in August 2026.
Obesity treatments: Two global Phase III programs for olatorepatide in obesity and obesity with type 2 diabetes are expected to initiate later this year.
Factor XI anticoagulation studies: Additional registrational studies in stroke prevention, cancer-associated venous thromboembolism, and other conditions are expected to commence this year, with initial results from knee replacement surgery studies anticipated in the first quarter of 2027.
Ophthalmology (Geographic Atrophy): Interim data from the exploratory cohort of the Phase III study in geographic atrophy is expected in the fourth quarter of 2026.
PNH (Paroxysmal Nocturnal Hemoglobinuria): Results from the registrational-enabling cohort of the Phase III study for cemdisiran plus pozelimab are expected late in the fourth quarter of 2026.
Fianlimab and Libtayo combination: Phase III study results in metastatic melanoma are expected later in the second quarter of 2026.
Rare diseases: Initial MASH siRNA program readouts targeting CIDEB, PNPLA3, and HSD17B13 are expected by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific details or announcements regarding a dividend program were mentioned in the transcript.
Share Repurchase Program: The Board authorized a new $3 billion share repurchase program, reflecting confidence in the business and financial position. Approximately $3.4 billion is now available for share repurchases, including the new authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss your willingness to work on life-cycle expansion efforts within the Sanofi collaboration for Dupixent?
A:Leonard Schleifer expressed openness to transactions leveraging development and commercial capabilities. He mentioned ongoing discussions with Sanofi's new CEO, Belén Garijo, and highlighted Dupixent's success as a financial juggernaut and its impact on millions of people.
Q:Is the PFS differentiation for fianlimab in metastatic melanoma enough to capture majority share, or is OS also needed?
A:George Yancopoulos stated that it depends on the results. The study is designed to show both PFS and OS benefits, but the results remain to be seen.
Q:Why did the FDA miss the April PDUFA for the EYLEA pre-filled syringe, and what is the guidance on timing for the applications?
A:Leonard Schleifer mentioned that the inspection at Catalent Indiana is pending, and if positive, the drug will be approved. He anticipates action on one or both applications during this quarter.
Q:What is the outlook for Lynozyfic in the multiple myeloma space, and how are you addressing infection risks in trials?
A:George Yancopoulos highlighted that bispecifics, including their own, show promising efficacy and tolerability profiles. He noted that infection risks decrease over time as the disease is controlled, and he believes their bispecifics could become the dominant class for treatment.
Q:How are you thinking about the importance of having a late-stage program for next-gen Dupixent before the U.S. IP expires?
A:Leonard Schleifer emphasized leveraging their knowledge in immunology and highlighted their pipeline of nearly 50 projects, including extended interval Dupixent and long-acting IL-13/IL-4 for allergic diseases and food allergies. He noted uncertainty around the patent expiration timeline.
Q:Should the co-injection of C5 with aflibercept be seen as a convenience play or a label expansion opportunity?
A:George Yancopoulos suggested it could serve both purposes, including preventing wet AMD and treating patients. He emphasized potential safety benefits and longer-acting versions compared to existing agents.
Q:What are the commercial considerations for developing the combo GLP-1/GIP plus Praluent?
A:George Yancopoulos explained that combining a best-in-class GLP with a PCSK9 inhibitor could provide significant cardiovascular benefits and weight loss. He highlighted competitive pricing and convenience as key factors, positioning it as a preferred option for patients.
Q:What is your clinical strategy to expedite development of next-gen I&I assets, particularly Supi-Dupi?
A:George Yancopoulos stated that they are well-positioned to accelerate programs based on their leadership and experience in the field.
Q:Where do you feel you have the most line of sight in the life cycle strategy for Dupixent?
A:Leonard Schleifer mentioned their extensive experience and capabilities, emphasizing efficiency in advancing Supi-Dupi and other projects within the collaboration with Sanofi.
Q:Can you provide color on the drivers of Libtayo's performance this quarter and its growth potential?
A:Marion McCourt attributed strong performance to advances in skin indications, particularly adjuvant CSCC, and enthusiasm for its clinical profile. She noted strong U.S. and international performance but mentioned some inventory movement favoring this quarter.
Q:What late-stage pipeline candidates do you have the greatest confidence in for generating multibillion-dollar peak sales?
A:Leonard Schleifer and George Yancopoulos highlighted several candidates, including the C5 franchise, anticoagulation programs, bispecifics like Lynozyfic and odronextamab, and obesity treatments. They emphasized their track record of producing blockbuster drugs.
Q:Why did you decide not to move fianlimab to Phase III in lung cancer, and is there any read-through to melanoma or other solid tumors?
A:George Yancopoulos explained that earlier data did not indicate a game-changing opportunity in lung cancer. He emphasized no negative read-through to melanoma or other solid tumors.
Q:What is the potential for systemic biologics in mild atopic dermatitis, and how can the market be broadened?
A:Marion McCourt noted unmet needs in mild disease and potential for systemic biologics. Leonard Schleifer highlighted the non-immunosuppressive nature of Dupixent and its safety profile, supporting earlier use in mild cases.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the life cycle strategy for Dupixent, particularly regarding Supi-Dupi, citing competitive reasons. Additionally, they did not elaborate on the FDA's reasons for missing the April PDUFA for EYLEA, only stating that inspections and approvals are pending.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADL endpoint
CFB
Dupixent sale
FDA approval
FDA decision
Hansoh Phase
III study
Libtayo CSCC
PNH
Phase III
Praluent
Regeneron
Telix
TriNetX
addition FDA
adult
age
application
approval Otarmeni
bone formation
cemdisiran
child year
complement
gene therapy
generation
hearing
interruption
olatorepatide
patient obesity
prevention
priority review
production
return
rhinosinusitis
science
share repurchase
site
stage
type
REGN Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call summary reflects strong financial performance with $848 million in revenue and growth potential driven by LIBTAYO and EYLEA HD. The Q&A session provides insights into strategic collaborations and product development, with management addressing concerns and emphasizing potential in various therapeutic areas. Despite some uncertainties, the company's robust pipeline and strategic initiatives, including share repurchases, suggest positive market sentiment. The absence of major negative factors and the focus on growth and shareholder returns support a positive stock price movement prediction.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-4
REGN Slides
Regeneron Q1 2026 slides: Dupixent drives 19% revenue growth2026-04-29
Regeneron Q4 2025 slides: Dupixent growth drives revenue, EYLEA HD gains momentum2026-01-30
Regeneron Q3 2025 slides: Dupixent drives growth as pipeline expands2025-10-28
Regeneron Q2 2025 slides: revenue rebounds to $3.68B after Q1 miss2025-08-01
REGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
